Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1Mentions an overnight / inpatient stay

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Eli Lilly and Company · NCT07738614

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
56
US sites recruiting
1
Study start
July 31, 2026
Record last updated
August 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.

Being studied: Eloralintide; Placebo; Acetaminophen

Conditions: Obesity; Overweight

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have overweight or obesity, but are otherwise overtly healthy.
  • Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.
  • Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.

Exclusion Criteria

  • Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening
  • A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or
  • Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol/mole (mol).
  • Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.
  • Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, or GIP/GLP-1/glucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.
  • Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.

Recruiting US locations

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Texas →
A Study of Eloralintide (LY3841136) in Participants With Obesity… (NCT07738614) | Bored Studies